Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to a fibrinogen-lowering agent and a prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal disorder comprising as an active component a compound having angiotensin II antagonistic activity (All antagonistic activity), a prodrug thereof, or a salt thereof.
• a fibrinogen-lowering agent and a prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal disorder comprising as an active component a compound having angiotensin II antagonistic activity (All antagonistic activity), a prodrug thereof, or a salt thereof.
• Plasma fibrinogen (FIB) levels have been identified as an independent risk factor for cardiovascular diseases. It has been reported that some fibrates lower circulating plasma fibrinogen levels. Fibrates, such as fenofibrate, are, effective in lowering elevated plasma triglyceride levels. The action of fibrates on lipid metabolism is thought to be revealed via the activation of the peroxisome proliferator activated receptor- ⁇ (PPAR ⁇ ). Treatment of rats with fenofibrate decreased hepatic fibrinogen mRNA levels. In addition, plasma fibrinogen levels of PPAR ⁇ -null mice were significant higher than those of wild-type mice. Thus, these results suggest that fibrate-suppressed plasma fibrinogen level is mediated through PPAR ⁇ (Blood, 93(9), 2991-2998 (1999)).
• All antagonistic activity are known to be therapeutic agents for circulatory system diseases such as hypertension, heart diseases (e.g. hypercardia, heart failure, and cardiac infarction), stroke, nephritis, etc (JP 4-364171 A, etc.). It is also known that a prolonged hypotensive effect can be obtained by blocking the action of All, which has a strong vasoconstrictive activity, on All receptor. However, no report suggests that compounds with All antagonistic activity have a fibrinogen-lowering activity.
• fibrinogen-lowering agent that has excellent medicinal properties such as, for example, excellent pharmacological effects for preventing and treating hyperfibrinogenemia and various diseases caused thereby without side effects.
• angiotensin II (AII) antagonistic activity particularly those represented by a certain specific formula are highly effective in lowering fibrinogen.
• compounds having renin-angiotensin inhibitory activity including compounds having angiotensin II antagonistic activity can be effective in preventing or treating hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal disorder.
• the present invention has been completed based on these findings.
• the present invention relates to:
• a compound having angiotensin II antagonistic activity, a prodrug thereof, or a salt thereof is advantageously used in lowering fibrinogen, etc.
• angiotensin II antagonistic activity refers to the effects of competitively or non-competitively inhibiting the bonding of angiotensin II to an angiotensin II receptor on cell membranes to diminish potent vasoconstrictive activity or vascular smooth muscle growth activity induced by angiotensin II to alleviate hypertension symptoms.
• the compound having angiotensin II antagonistic activity to be used for the present invention may be either a peptide compound or a non-peptide compound.
• a non-peptide compound having angiotensin II antagonistic activity is preferable.
• the compound having angiotensin II antagonistic activity a compound having oxygen atom in its molecule is preferable, a compound having ether linkage or carbonyl group (said carbonyl group may form hydroxyl group by resonance) is more preferable, a compound having an ether linkage or a ketone derivative is further preferable, and in particular, an ether derivative is preferable.
• any non-peptide compound having angiotensin II antagonistic activity can be used for the present invention.
• said compounds include imidazole derivatives disclosed in JP 56-71073 A, JP 56-71074 A, JP 57-98270 A, JP 58-157768 A, USP 4,355,040, USP 4,340,598, etc.; modified imidazole derivatives disclosed in EP-253310, EP-291969, EP-324377, EP-403158, WO-9100277, JP 63-23868 A, JP 1-117876 A, etc.; pyrrole, pyrazole and triazole derivatives disclosed in USP 5,183,899, EP-323841, EP-409332, JP 1-287071 A, etc.; benzimidazole derivatives disclosed in USP 4,880,804, EP-0392317, EP-0399732, EP-0400835, EP-425921, EP-459136, JP 3-63264 A, etc.; azaindene
• Losartan (DuP753), Eprosartan (SK&F108566), Candesartan cilexetil (TCV-116), Valsartan (CGP-48933), Telmisartan (BIBR277), Irbesartan (SR47436), Tasosartan (ANA-756), Olmesartan (CS-866), their active metabolites (Candesartan, etc.), etc. are preferable.
• Preferred examples of the non-peptide compound having angiotensin II antagonistic activity include, for example, a benzimidazole derivative of the formula (I): wherein R 1 is a group capable of forming an anion or a group capable of converting thereinto, X shows that the phenylene group and the phenyl group bind to each other directly or through a spacer having an atomic chain length of 2 or less, n is an integer of 1 or 2, ring A is benzene ring which may be further substituted, R 2 is a group capable of forming an anion or a group capable of converting thereinto, and R 3 is an optionally substituted hydrocarbon residue which may bind through a hetero-atom (preferably, an optionally substituted hydrocarbon residue which binds through oxygen atom), etc., or a salt thereof.
• R 1 is a group capable of forming an anion or a group capable of converting thereinto
• X shows that the phenylene group and the phenyl
• the group capable of forming an anion (a group having hydrogen atom capable of leaving as a proton) as R 1 include, for example, (1) carboxyl group, (2) tetrazolyl group, (3) trifluoromethanesulfonic acid amido group (-NHSO 2 CF 3 ), (4) phosphono group, (5) sulfo group, (6) an optionally substituted 5- to 7-membered (preferably 5- to 6-membered) monocyclic heterocyclic ring residue which contains one or more of N, S and O, etc.
• Examples of the above "optionally substituted 5- to 7-membered (preferably 5- to 6-membered) monocyclic heterocyclic ring residue which contains one or more of N, S and 0" include etc.
• the chemical bond between the heterocyclic ring residue represented by R 1 and the phenyl group to which said heterocyclic ring residue binds may be a carbon-carbon bond as shown above, or a nitrogen-carbon bond via one of the several nitrogen atoms when the symbol g is -NH-, etc. in the above formulas.
• R 1 when R 1 is represented by the formula: its specific embodiments are Other examples of R 1 binding through a nitrogen atom include etc.
• Preferred examples of the heterocyclic ring residue represented by R 1 include a heterocyclic ring residue simultaneously having -NH- or -OH group as proton donor and carbonyl group, thiocarbonyl group, sulfinyl group, etc. as proton acceptor, such as oxadiazolone ring, oxadiazolothione ring or thiadiazolone ring, etc.
• heterocyclic ring residue represented by R 1 may form a condensed ring by connecting the substituents on the heterocyclic ring, it is preferably 5- to 6-membered ring residue, more preferably 5-membered ring residue.
• the above-mentioned heterocyclic ring residue (R 1 ) has the following tautomeric isomers.
• Z is 0 and g is 0, the three tautomeric isomers a', b' and c' exist and a group of the formula: include all of the above a', b' and c'.
• the group capable of forming an anion as R 1 may be protected by an optionally substituted lower (C 1-4 ) alkyl group, an acyl group (e.g., lower (C 2-5 ) alkanoyl, benzoyl, etc.), etc. at its possible position.
• an optionally substituted lower (C 1-4 ) alkyl group an acyl group (e.g., lower (C 2-5 ) alkanoyl, benzoyl, etc.), etc. at its possible position.
• Examples of the optionally substituted lower (C 1-4 ) alkyl group include (1) a lower (C 1-4 ) alkyl group optionally substituted with one to three phenyl groups which may have halogen atom, nitro, lower (C 1-4 ) alkyl, lower (C 1-4 ) alkoxy, etc.
• R 4 is (a) hydrogen, (b) a straight or branched lower C 1-6 alkyl group (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, etc.), (c) a straight or branched lower C 2-6 alkenyl group or (d) a C 3-8 cycloalkyl group (e.g., cyclopentyl, cyclohe
• alkenyl moiety such as vinyl, propenyl, allyl, isopropenyl, etc.
• an optionally substituted aryl group e.g., a phenyl group, naphthyl group, etc., optionally having a halogen atom, nitro, a lower (C 1-4 ) alkyl, a lower (C 1-4 ) alkoxy, etc.
• a straight or branched lower C 1-6 alkoxy group e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, etc.
• a straight or branched lower C 2-8 alkenyloxy group e.g., ally
• a lower C 2-3 alkenyloxy group substituted with a C 3-8 cycloalkyl e.g., cyclopentyl, cyclohexyl, cycloheptyl, etc.
• an optionally substituted aryl group e.g., phenyl group or naphthyl group, etc., optionally having a halogen atom, a nitro, a lower (C 1-4 ) alkyl, a lower (C 1-4 ) alkoxy, etc.
• cinnamyloxy etc.
• an alkenyloxy moiety such as vinyloxy, propenyloxy, allyloxy, isopropenyloxy, etc. or (k) an optionally substituted aryloxy group (e.g., a phenoxy group, a naphthoxy group, etc., optionally having a halogen atom, nitro, a lower (C 1-4 ) alkyl, a lower (C 1-4 ) alkoxy, etc.) such as phenoxy, p-nitrophenoxy, naphthoxy, etc.; etc.
• aryloxy group e.g., a phenoxy group, a naphthoxy group, etc., optionally having a halogen atom, nitro, a lower (C 1-4 ) alkyl, a lower (C 1-4 ) alkoxy, etc.
• the group capable of forming an anion as R 1 may be substituted, in addition to the above protective group such as an optionally substituted lower (C 1-4 ) alkyl group or an acyl group (e.g., lower (C 2-5 ) alkanoyl, benzoyl, etc.), etc., with an optionally substituted lower (C 1-4 ) alkyl group (e.g.
• an optionally substituted lower (C 1-4 ) alkyl group similar to the "optionally substituted lower (C 1-4 ) alkyl group" exemplified as a protective group for the above group capable of forming an anion as R 1 ), a halogen atom, nitro, cyano, a lower (C 1-4 ) alkoxy, an amino optionally substituted with 1 to 2 lower (C 1-4 ) alkyl groups, etc., at the possible position.
• the group convertible into the group capable of forming an anion (a group having a hydrogen atom capable of leaving as proton) as R 1 may be a group convertible into a group capable of forming an anion under biological or physiological conditions (for example, in vivo reaction, etc. such as oxidation, reduction, hydrolysis, etc.
• cyano N-hydroxycarbamimidoyl group
• -NHSO 2 CF 3 trifluoromethane
• carboxyl, tetrazolyl or 4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl (preferably, tetrazolyl), each of which may be protected with an optionally substituted lower (C 1-4 ) alkyl (e.g., methyl, triphenylmethyl, methoxymethyl, ethoxymethyl, p-methoxybenzyl, p-nitrobenzyl, etc.) or an acyl group (e.g., lower (C 2-5 ) alkanoyl, benzoyl, etc.); or cyano or N-hydroxycarbamimidoyl (preferably cyano) is preferable. Among others, cyano is preferable.
• C 1-4 alkyl e.g., methyl, triphenylmethyl, methoxymethyl, ethoxymethyl, p-methoxybenzyl, p-nitrobenzyl, etc.
• an acyl group e.g., lower
• X shows that the phenylene group is bonded to the adjacent phenyl group directly or through a spacer with an atomic chain of 2 or less (preferably directly).
• n is an integer of 1 or 2 (preferably 1).
• ring A may have, in addition to the group R 2 , another substituent, for example, (1) halogen (e.g., F, Cl, Br, etc.), (2) cyano, (3) nitro, (4) an optionally substituted lower (C 1-4 ) alkyl, (5) a lower (C 1-4 ) alkoxy, (6) an optionally substituted amino group (e.g., amino, N-lower (C 1-4 ) alkylamino (e.g., methylamino, etc.), N,N-di-lower (C 1-4 ) alkylamino (e.g., dimethylamino, etc.), N-arylamino (e.g., phenylamino, etc.), alicyclic amino (e.g., morpholino, piperidino, piperazino, N -phenylpiperazino, etc.), etc.), (7) a group of the formula: -CO-D' wherein D' is
• substituents for the benzene ring represented by A in addition to the group R 2 include an optionally substituted lower (C 1-4 ) alkyl (e.g., a lower (C 1-4 ) alkyl, etc. optionally substituted with a hydroxyl group, a carboxyl group, a halogen, etc.), a halogen , etc.
• ring A benzene ring having no substituent in addition to the group R 2 is preferable.
• examples of the group capable of forming an anion (a group having a hydrogen atom capable of leaving as proton) as R 2 include (1) an optionally esterified or amidated carboxyl group, (2) tetrazolyl group, (3) trifluoromethanesulfonic acid amido group (-NHSO 2 CF 3 ), (4) phosphono group, (5) sulfo group, etc., each of which may be protected with an optionally substituted lower alkyl group (e.g.
• an optionally substituted lower (C 1-4 ) alkyl group similar to the "optionally substituted lower (C 1-4 ) alkyl group" exemplified as a protective group for the above group capable of forming an anion as R 1 ) or an acyl group (e.g., lower (C 2-5 ) alkanoyl, benzoyl, etc.), or any one of the groups capable of converting thereinto under biological or physiological conditions (for example, in vivo reaction, etc. such as oxidation, reduction, hydrolysis, etc. by in vivo enzyme, etc.), or chemically.
• an optionally substituted lower (C 1-4 ) alkyl group similar to the "optionally substituted lower (C 1-4 ) alkyl group" exemplified as a protective group for the above group capable of forming an anion as R 1 ) or an acyl group (e.g., lower (C 2-5 ) alkanoyl, benzoyl, etc.), or any one of the
• Examples of the optionally esterified or amidated carboxyl as R 2 include a group of the formula: -CO-D wherein D is (1) a hydroxyl group, (2) an optionally substituted amino (for example, amino, N-lower (C 1-4 ) alkylamino, N,N-di-lower (C 1-4 ) alkylamino, etc.) or (3) an optionally substituted alkoxy [e.g., (i) a lower (C 1-6 ) alkoxy group whose alkyl moiety is optionally substituted with hydroxyl group, an optionally substituted amino (e.g., amino, N-lower (C 1-4 ) alkylamino, N,N-di-lower (C 1-4 ) alkylamino, piperidino, morpholino, etc.), a halogen, a lower (C 1-6 ) alkoxy, a lower (C 1-6 ) alkylthio, a lower (C 3-8 ) cycl
• alkenyl moiety such as vinyl, propenyl, allyl, isopropenyl, etc.
• an optionally substituted aryl group e.g., phenyl group, naphthyl group, etc., optionally having a halogen atom, nitro, a lower (C 1-4 ) alkyl, a lower (C 1-4 ) alkoxy, etc.) such as phenyl, p-tolyl, naphthyl, etc.
• a straight or branched lower C 1-6 alkoxy group e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, etc.
• a straight or branched lower C 2-8 alkenyloxy group e.g., allyloxy
• a lower C 2-3 alkenyloxy group substituted with a C 3-8 cycloalkyl e.g., cyclopentyl, cyclohexyl, cycloheptyl, etc.
• an optionally substituted aryl group e.g., phenyl group or naphthyl group, etc., optionally having a halogen atom, a nitro, a lower (C 1-4 ) alkyl, a lower (C 1-4 ) alkoxy, etc.
• cinnamyloxy etc.
• an optionally substituted aryloxy group e.g., a phenoxy group, a naphthoxy group, etc., optionally having a halogen atom, a nitro, a lower (C 1-4 ) alkyl, a lower (C 1-4 ) alkoxy, etc.
• aryloxy group e.g., a phenoxy group, a naphthoxy group, etc., optionally having a halogen atom, a nitro, a lower (C 1-4 ) alkyl, a lower (C 1-4 ) alkoxy, etc.
• an optionally esterified carboxyl is preferable, and its specific examples include -COOH and a salt thereof, -COOMe, -COOEt, -COOtBu, -COOPr, pivaloyloxymethoxycarbonyl, 1-(cyclohexyloxycarbonyloxy)ethoxycarbonyl, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethoxycarbonyl, acetoxymethoxycarbonyl, propionyloxymethoxycarbonyl, n-butyryloxymethoxycarbonyl, isobutyryloxymethoxycarbonyl, 1-(ethoxycarbonyloxy)ethoxycarbonyl, 1-(acetoxy)ethoxycarbonyl, 1-(isobutyryloxy)ethoxycarbonyl, cyclohexylcarbonyloxymethoxycarbonyl, benzoyloxymethoxycarbonyl, cinnamyloxycarbon
• the group R 2 may be any one of the groups capable of forming an anion under biological or physiological conditions (for example, in vivo reaction, etc. such as oxidation, reduction, hydrolysis, etc. by in vivo enzyme, etc.), the groups capable of chemically forming an anion (e.g., COO-, its derivative, etc.) or the groups capable of converting thereinto.
• the group R 2 may be a carboxyl group or its pro-drug.
• Preferred examples of the group R 2 include a group of the formula: -CO-D wherein D is (1) hydroxyl group or (2) a lower (C 1-4 ) alkoxy whose alkyl moiety is optionally substituted with a hydroxyl group, an amino, a halogen , a lower (C 2-6 ) alkanoyloxy (e.g., acetoxy, pivaloyloxy , etc.), a lower (C 3-8 ) cycloalkanoyloxy, a lower (C 1-6 ) alkoxycarbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, etc.), a lower (C 3-8 ) cycloalkoxycarbonyloxy (e.g., cyclohexyloxycarbonyloxy, etc.), a lower (C 1-4 ) alkoxy or a lower (C 3-8 ) cycloalkoxy.
• D is (1) hydroxyl group or (2)
• examples of the "hydrocarbon residue" in the "optionally substituted hydrocarbon residue which may bind through a hetero-atom” represented by R 3 include (1) an alkyl group, (2) an alkenyl group, (3) an alkynyl group, (4) a cycloalkyl group, (5) an aryl group, (6) an aralkyl group, etc.
• an alkyl group, an alkenyl group and a cycloalkyl group are preferable.
• alkyl group of the above mentioned (1) examples include straight or branched lower alkyl group having about 1-8 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, i-pentyl, hexyl, heptyl, octyl, etc.
• alkenyl group of the above mentioned (2) examples include straight or branched lower alkenyl group having about 2-8 carbon atoms such as vinyl, propenyl, 2-butenyl, 3-butenyl, isobutenyl, 2-octenyl, etc.
• alkynyl group of the above mentioned (3) examples include straight or branched lower alkynyl group having about 2-8 carbon atoms such as ethynyl, 2-propynyl, 2-butynyl, 2-pantynyl, 2-octynyl, etc.
• Examples of the cycloalkyl group of the above (4) include a lower cycloalkyl having about 3-6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
• Each of the above-mentioned alkyl group, alkenyl group, alkynyl group and cycloalkyl group may be substituted with hydroxyl group, an optionally substituted amino group (e.g., amino, N-lower (C 1-4 ) alkylamino, N,N-di-lower (C 1-4 ) alkylamino, etc.), halogen , lower (C 1-4 ) alkoxy group, lower (C 1-4 ) alkylthio group, etc.
• an optionally substituted amino group e.g., amino, N-lower (C 1-4 ) alkylamino, N,N-di-lower (C 1-4 ) alkylamino, etc.
• halogen lower (C 1-4 ) alkoxy group
• lower (C 1-4 ) alkylthio group etc.
• Examples of the aralkyl group of the above (5) include a phenyl-lower (C 1-4 ) alkyl, etc., such as benzyl, phenethyl, etc.
• Examples of the aryl group of the above (6) include phenyl, etc.
• Each of the above-mentioned aralkyl group and aryl group may be substituted, at any possible position on the benzene ring, with a halogen (e.g., F, Cl, Br, etc.), a nitro, an optionally substituted amino group (e.g., amino, N-lower (C 1-4 ) alkylamino, N,N-di-lower (C 1-4 ) alkylamino, etc.), a lower (C 1-4 ) alkoxy (e.g., methoxy, ethoxy, etc.), a lower (C 1-4 ) alkylthio (e.g., methylthio, ethylthio, etc.), a lower (C 1-4 ) alkyl (e.g., methyl, ethyl, etc.), etc.
• a halogen e.g., F, Cl, Br, etc.
• a nitro an optionally substituted amino group
• Preferred examples of the "optionally substituted hydrocarbon residue" in the "optionally substituted hydrocarbon residue which may bind through a hetero-atom” represented by R 3 include an optionally substituted alkyl or alkenyl group (e.g., a lower (C 1-5 ) alkyl or a lower (C 2- - 5 ) alkenyl group, each of which may be substituted with a hydroxyl group, an amino group, a halogen, a lower (C 1-4 ) alkoxy group, etc.).
• a lower (C 1-5 ) alkyl is preferable.
• hetero-atom in the "optionally substituted hydrocarbon residue which may bind through a hetero-atom” represented by R 3
• R 3 Preferred examples of the "hetero-atom" in the "optionally substituted hydrocarbon residue which may bind through a hetero-atom” represented by R 3 include -O-, -S(O)m- [m is an integer of 0 to 2], -NR'- [R' is a hydrogen atom or a lower (C 1-4 ) alkyl], etc.
• -O- is preferable.
• R 3 -a lower (C 1-5 ) alkyl or a lower (C 2-5 ) alkenyl group, each of which may be substituted with a substituent selected from the class consisting of a hydroxyl group, an amino group, a halogen and a lower (C 1-4 ) alkoxy group and which may bind through -O-, -S(O) m - [m is an integer of 0-2] or -NR'- [R' is a hydrogen atom or a lower (C 1-4 ) alkyl], etc. is preferable and a lower (C 1-5 ) alkyl or lower (C 1-5 ) alkoxy (in particular, ethoxy) is more preferable.
• the ring A is a benzene ring having an optional substituent selected from the class consisting of an optionally substituted lower (C 1-4 ) alkyl (e.g., a lower (C 1-4 ) alkyl optionally substituted with a hydroxyl group, a carboxyl group, a halogen, etc.) and a halogen, in addition to the group R 2 (preferably, a benzene ring having no substituent in addition to the group R 2 ) ;
• R 2 is a group of the formula: -
• benzimidazole derivative can be produced by known methods described in, for example, EP-425921, EP-459136, EP-553879, EP-578125, EP-520423, EP-668272, etc. or a method analogous thereto.
• Candesartan cilexetil is used for the present invention, a stable C-type crystal described in EP-459136 is preferably used.
• the compound having angiotensin II antagonistic activity or a pro-drug thereof may be distinct entity or in the form of any possible pharmaceutically acceptable salts thereof.
• said salts include a salt with inorganic bases (e.g., alkaline metals such as sodium, potassium, etc.; alkaline earth metals such as calcium, magnesium, etc.; transition metal such as zinc, iron, copper, etc.; etc.); organic bases (e.g., organic amines such as trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc.; basic amino acids such as arginine, lysine, ornithine, etc.; etc.); etc., when said compound having angiotensin II antagonistic activity has an acidic group such as a carboxyl group, etc.; and a salt with inorganic acids or organic acids (e.g., hydro
• the pro-drug of the compound having angiotensin II antagonistic activity means a compound which is converted to All antagonist under the physiological condition or with a reaction due to an enzyme, an gastric acid, etc. in the living body, that is, a compound which is converted to All antagonist with oxidation, reduction, hydrolysis, etc. according to an enzyme; a compound which is converted to All antagonist with gastric acid, etc.; etc.
• Examples of the pro-drug of the All antagonist include a compound wherein an amino group of the All antagonist is substituted with acyl, alkyl, phosphoric acid, etc. (e.g. a compound wherein an amino group of the All antagonist is substituted with eicosanoyl, alanyl, pentylaminocarbonyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonyl, tetrahydrofuranyl, pyrrolidylmethyl, pivaloyloxymethyl, tert-butyl, etc.); a compound wherein an hydroxyl group of the All antagonist is substituted with acyl, alkyl, phosphoric: acid, boric acid, etc.
• a compound wherein hydroxyl group of the All antagonist is substituted with acetyl, palmitoyl, propanoyl, pivaloyl, succinyl, fumaryl, alanyl, dimethylaminomethylcarbonyl, etc.
• a compound wherein a carboxyl group of the All antagonist is modified with ester, amide, etc.
• carboxyl group of the All antagonist is modified with ethyl ester, phenyl ester, carboxymethyl ester, dimethylaminomethyl ester, pivaloyloxymethyl ester, ethoxycarbonyloxyethyl ester, phthalidyl ester, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl ester, cyclohexyloxycarbonylethyl ester, methyl amide, etc.); etc.
• pro-drug can be produced by per se known method from the All antagonist.
• the pro-drug of the All antagonist may be a compound which is converted into the AII antagonist under the physiological conditions as described in "Pharmaceutical Research and Development", Vol. 7 (Drug Design), pages 163-198 published in 1990 by Hirokawa Publishing Co. (Tokyo, Japan).
• All antagonist may be hydrated.
• the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof is low in toxicity and can be administered as it is, or as a pharmaceutical composition thereof with a pharmaceutically acceptable carrier, to mammals (e.g., men, mice, rats, rabbits, dogs, cats, bovines, pigs, monkeys, etc.) as a fibrinogen lowering agent.
• mammals e.g., men, mice, rats, rabbits, dogs, cats, bovines, pigs, monkeys, etc.
• examples of the pharmaceutically acceptable carrier include various organic or inorganic carriers which are generally used in this field.
• an excipient, a lubricant, a binder, an disintegrating agent, etc. are used in solid formulations, and a solvent, a solubilizer, a suspending agent, a isotonizing agent, a buffer, a soothing agent, etc. are used in liquid formulations.
• an appropriate additive such as a preservative, an antioxidant, a colorant, a sweetener, etc. may be used in the above formulations.
• excipient examples include lactose, sucrose, D-mannitol, D-sorbitol, starch, ⁇ -starch, dextrin, crystalline cellulose, hydroxypropyl cellulose with a low degree of substitution, sodium carboxymethyl cellulose, gum arabic, dextrin, pullulan, light silic acid anhydride, synthesized aluminum silicate, magnesium aluminate metasilicate, etc.
• lubricant examples include magnesium stearate, calcium stearate, talc, colloidal silica, etc.
• binder examples include ⁇ -starch, sucrose, gelatin, gum arabic, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, sugar, D-mannitol, trehalose, dextrin, pullulan, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl--pyrrolidone, etc.
• disintegrating agent examples include lactose, sugar, starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, sodium carboxymethyl starch, light silic acid anhydride with a low degree of substitution, hydroxypropyl cellulose, etc.
• solvent examples include water for injection, Ringer solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil, etc.
• solubilizer examples include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate, etc.
• suspending agent examples include surfactants such as stearyl triethanolamine, sodium laurylsulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzetonium chloride, glycerin monostearate, etc.; hydrophilic polymers such as polyvinylalcohol, polyvinylpyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc.; polysorbates, polyoxyethylene hardened caster oil, etc.; etc.
• surfactants such as stearyl triethanolamine, sodium laurylsulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzetonium chloride, glycerin monostearate, etc.
• hydrophilic polymers such as polyvinylalcohol, polyvinylpyrrolidone, sodium carboxymethyl
• isotonizing agent examples include sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, etc.
• Examples of the buffer include a buffer solution of phosphate, acetate, carbonate, citrate, etc.
• Examples of the soothing agent include benzylalcohol, etc.
• preservative examples include paraoxybenzoic acid esters, chlorobutanol, benzylalcohol, phenethylalcohol, dehydroacetic acid, sorbic acid, etc.
• antioxidant examples include sulfites, ascorbic acid, etc.
• colorants include water-soluble synthetic organic food additives (e.g., food dyes such as food red dye Nos. 2 and 3, food yellow dye Nos. 4 and 5 and food 'blue dye Nos. 1 and 2), water-insoluble lake dyes (e.g., aluminum salts of the above water-soluble synthetic organic food additives, etc.), natural pigments (e.g., ⁇ -carotene, chlorophyll, iron oxide red, etc.), etc.
• water-soluble synthetic organic food additives e.g., food dyes such as food red dye Nos. 2 and 3, food yellow dye Nos. 4 and 5 and food 'blue dye Nos. 1 and 2
• water-insoluble lake dyes e.g., aluminum salts of the above water-soluble synthetic organic food additives, etc.
• natural pigments e.g., ⁇ -carotene, chlorophyll, iron oxide red, etc.
• sweeteners include sodium saccharate, glycyrrhizin dipotassium, aspartame, Stevia, etc.
• the pharmaceutical composition is orally or parenterally administered in safety in the form of, for example, orally administered compositions such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, suspensions, etc.; and parenterally administered compositions such as injectable preparations (e.g., sustained release injectable preparation, subcutaneous injectable preparation, intravenous injectable preparation, intramuscular injectable preparation, intraperitoneal injectable preparation, intravitreous injectable preparation, etc.), drops, medicines for external use (e.g., compositions for nasotracheally administration, compositions for percutaneously administration, ointments, etc.), suppositories (e.g., rectal suppository, vaginal suppository, etc.), pellets, drops, and the like.
• injectable preparations e.g., sustained release injectable preparation, subcutaneous injectable preparation, intravenous injectable preparation, intramuscular injectable preparation, intraperitoneal
• the pharmaceutical composition can be prepared according to any of conventional methods in the field of pharmaceutical compositions, for example, according to the procedure described in the Japanese Pharmacopoeia. Hereinafter, a specific method of preparing the pharmaceutical composition will be described in detail.
• the pharmaceutical composition contains the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof in an amount of about 0.001% by weight to about 95% by weight, preferably about 0.1% by weight to about 70% by weight based on the total weight of the composition.
• a pharmaceutical composition to be orally administered is prepared by adding to the active component an excipient (e.g., lactose, sugar, starch, D-mannitol, etc.), disintegrating agent (e.g., carboxymethyl cellulose calcium, etc.), binder (e.g., ⁇ -starch, gum arabic, carboxymethyl cellulose, hydroxypropyl cellulose, polyvinyl-pyrrolidone, etc.), lubricant (e.g., talc, magnesium stearate, polyethylene glycol 6000, etc.), etc., and compression-molding the mixture composition, and if necessary, coating the composition with a coating base material by a known method so as to mask the taste, to form enteric coating, or to obtain long lasting activity.
• excipient e.g., lactose, sugar, starch, D-mannitol, etc.
• disintegrating agent e.g., carboxymethyl cellulose calcium, etc.
• binder e.g.,
• coating base material examples include sugar coating material, water-soluble film coating material, enteric film coating material, sustained release film coating material, etc.
• sugar is used, which may be used in combination with at least one material selected from talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, carnauba wax, etc.
• water-soluble film coating material examples include cellulose polymers such as hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, and methyl hydroxyethyl cellulose; synthesized polymers such as polyvinyl acetal diethylaminoacetate, aminoalkylmethacrylate copolymer E [Eudragit E (trade name), Rhom Pharma], polyvinyl-pyrrolidone, etc.; polysaccharides such as pullulan, etc.
• cellulose polymers such as hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, and methyl hydroxyethyl cellulose
• synthesized polymers such as polyvinyl acetal diethylaminoacetate, aminoalkylmethacrylate copolymer E [Eudragit E (trade name), Rhom Pharma], polyvinyl-pyrrolidone, etc.
• polysaccharides such as pullulan, etc.
• enteric film coating material examples include cellulose polymers such as hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, carboxymethylethyl cellulose, cellulose acetate phthalate, etc.; acrylic polymers such as methacrylate copolymer LD [Eudragit L-30D55 (trade name), Rhom Pharma], methacrylic copolymer S [Eudragit S (trade name), Rhom Pharma]; and natural substances such as shellac, etc.
• cellulose polymers such as hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, carboxymethylethyl cellulose, cellulose acetate phthalate, etc.
• acrylic polymers such as methacrylate copolymer LD [Eudragit L-30D55 (trade name), Rhom Pharma], methacrylic copolymer S [Eudragit S (trade name), Rhom Pharma]
• natural substances such as shellac, etc.
• sustained release film coating materials examples include cellulose polymers such as ethyl cellulose; and acrylate polymers such as aminoalkyl methacrylate copolymer RS[Eudragit RS (trade name), Rhom Pharma], ethyl acrylate methyl methacrylate copolymer suspension [Eudragit NE (trade name), Rhom Pharma], etc.
• cellulose polymers such as ethyl cellulose
• acrylate polymers such as aminoalkyl methacrylate copolymer RS[Eudragit RS (trade name), Rhom Pharma], ethyl acrylate methyl methacrylate copolymer suspension [Eudragit NE (trade name), Rhom Pharma], etc.
• Each of the above coating materials may be used as a mixture with at least two thereof in a proper ratio.
• a light-shielding material such as titanium oxide, iron sesquioxide or the like may be used in the course of coating.
• the injectable preparation is prepared by dissolving, suspending or emulsifying the active component in an aqueous solvent (e.g., distilled water, physiological salt solution, Ringer solution, etc.), an oil solvent (e.g., vegetable oils such as olive oil, sesame oil, cottonseed oil, corn oil, and propylene glycol, etc.) or the like together with a dispersant (e.g., polysorbate 80, polyoxyethylene hardened caster oil 60, etc.), polyethylene glycol, carboxymethyl cellulose, sodium alginate, etc.), preservative (e.g., methyl paraben, propyl paraben, benzylalcohol, chlorobutanol, phenol, etc.), isotonizing agent (e.g., sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, etc.) or the like.
• an aqueous solvent e.g., distilled water, physiological salt solution, Ringer
• additives such as a solubilizer (e.g., sodium salycylate, sodium acetate, etc.), stabilizer (e.g., human serum albumin, etc.), soothing agent (e.g., benzylalcohol, etc.) and the like may be used.
• solubilizer e.g., sodium salycylate, sodium acetate, etc.
• stabilizer e.g., human serum albumin, etc.
• soothing agent e.g., benzylalcohol, etc.
• the pharmaceutical composition of the present invention is preferably formulated into a sustained release preparation.
• sustained release preparation examples include:
• sustained release preparations can be prepared and used according to the description in EP-A-1058541.
• Examples of another aspect of the sustained release preparation include:
• sustained release preparations can be prepared and used according to the description in PCT/JP01/01191.
• the dosage of the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof varies depending on a particular subject, administration route, disease, symptom, etc.
• the active component of the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof is orally administered to a mammal, specifically an adult (body weight 50 kg) with hyperfibrinogenemia in a dose of about 0.001 to 500 mg, preferably 0.1 to 50 mg, preferably once to three times per day.
• the fibrinogen-lowering agent of the present invention is used as a prophylactic or therapeutic agent for fibrinogen-related diseases of mammals (e.g. human, mouse, rat, rabbit, dog, cat, bovine, horse, pig, monkey, etc.).
• the fibrinogen-related diseases include any disease that is induced in the presence of fibrinogen and can be treated through the effect of lowering fibrinogen level.
• Examples of such a disease include hypercardia, chronic heart failure including stagnant heart failure, angina pectoris, arrhythmia, myocardial infarction, hyperfibrinogenemia induced ischemic heart diseases of nephrosis patients, silent cerebrovascular accident, transient brain ischemic attack, RIND, stroke, brain vascular dementia, neural symptoms in acute phase of brain thrombosis, lacunar infarct, brady-progressive brain thrombosis, hyperfibrinogenemia induced ischemic brain and heart diseases, cerebral edema, brain circulatory disorders, recurrence and sequelae of cerebrovascular disorders (e.g.
• ischemic peripheral circulatory disorders myocardial ischemia, venous dysfunction, progress of heart failure after myocardial infarction, diabetes, diabetic complications (e.g. diabetic retinopathy, diabetic nephropathy, and diabetic neural disorders), nephritis, glomerulonephritis, glomerulosclerosis, renal failure, microangiopathy, dialysis complications, hyperfibrinogenemia induced ischemic brain and heart diseases of dialysis patients, hyperfibrinogenemia induced deterioration of nephrosis patients' kidney function, radiation induced organopathy including nephropathy, acute renal failure associated with endotoxin shock, acute renal failure associated with ischemia, deterioration of renal diseases caused by fibrin deposition on renal glomerulus, prophylaxis of blood coagulation in using apparatus for hemodialysis or other extracorporeal circulations, prophylaxis of blood coagulation
• percutaneous transluminal coronary angioplasty percutaneous transluminal coronary revascularization, stent implantation, coronary endoscopy, intravascular ultrasonography, and coronary injection thrombolytic therapy
• vascular reobstruction or reconstriction after bypass surgery organopathy or vascular hypertrophy after grafting, thrombosis, multiorgan failure, endothelium dysfunction, obstructive peripheral circulatory disorder, ischemic brain circulatory disorders, limb ulcer associated with chronic artery obstruction (e.g.
• Buerger's disease and arteriosclerosis obliterans resting gout and psychroesthesia, lower limb gangrene, bloodstream disorders .caused by cerebrovascular contraction after subarachnoid hemorrhage surgery, metabolic disorders (e.g. obesity, syndrome X, hyperlipemia, hypercholesterolemia, diabetes, and glucose tolerance abnormality), central nervous disorders (e.g.
• disorders such disorders as brain infarct and sequelae and complications thereof, head injury, spinal injury, cerebral edema, sensory dysfunction, autonomic dysfunction, and multiple sclerosis
• dementia memory disorder, consciousness disorder, amnesia, anxiety symptoms, catatonic symptoms, dysphoric mental symptoms, acute inflammatory reactions, retinopathy, nephropathy, neuropathy, diabetes complications such as great vessel disorders, chronic articular rheumatism, allergic rhinitis, anaphylaxis, collagenosis, renal failure associated with systemic lupus erythematosus, hepatitis including chronic hepatitis, cirrhosis, Kawasaki disease, thrombosis in pregnancy, thrombosis in oral contraceptive intake, septicemia, acute renal failure associated with sepsis, endotoxin shock, Gram-negative sepsis, toxin shock syndrome, Mérier syndrome, vertigo, balance disorders, dysphagia, deafness, keloid, angioma,
• the present invention also includes a prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal disorder (e.g. a renal dysfunction associated with glomerulonephritis, glomerulosclerosis, interstitial nephritis, nephrosclerosis, or polycystic renal diseases), which comprises a compound having renin-angiotensin inhibitory activity, a prodrug thereof, or a salt thereof.
• a renal disorder e.g. a renal dysfunction associated with glomerulonephritis, glomerulosclerosis, interstitial nephritis, nephrosclerosis, or polycystic renal diseases
• Examples of the compound having renin-angiotensin inhibitory activity to be used include one or more (preferably two or three) compounds selected from the group consisting of (1) the above-mentioned All antagonist compound, (2) a compound having angiotensin converting enzyme (ACE) inhibitory activity, (3) a compound having renin inhibitory activity, (4) a compound having chymase inhibitory activity, and (5) compound having an aldosterone antagonistic activity.
• ACE angiotensin converting enzyme
• ACE-inhibiting compound examples include enalapril, lisinopril, and omapatrilat (BMS-186716), whose albuminuria suppressing activities have been described in many reports, and compounds (protease inhibitors) having both ACE inhibitory activity and NEP (neutral endopeptidase) inhibitory activity.
• the compound having both ACE and NEP inhibitory activities is known as a drug for treating hypertension by inhibiting production of angiotensin II and decomposition of atrial natriuretic peptide (ANP having the effects of reducing humor volume and vasodilation) and expected for its utility to therapeutic pharmaceuticals for failures, for example, including omapatrilat and sampatrilat (UK-81252; Pfiser).
• Examples of the compound having renin inhibitory activity include SPP-100 (Novartis), etc.
• Examples of the compound having chymase inhibitory activity include NK3201 (NIPPON KAYAKU), etc.
• Examples of the compound having aldosterone antagonistic activity include SC-66100 (Pharmacia), etc.
• Prodrugs or salts of these compounds may also be used and examples thereof include those exemplified with respect to the above-mentioned compound having All antagonistic activity.
• the compound having renin-angiotensin inhibitory activity, a prodrug thereof, or a salt thereof is less toxic and can be used for a prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal disorder in mammals (e.g. human, mouse, rat, rabbit, dog, cat, bovine, pig, monkey, etc.) as it is or in the form of a pharmaceutical composition comprising it and a pharmaceutically acceptable carrier.
• mammals e.g. human, mouse, rat, rabbit, dog, cat, bovine, pig, monkey, etc.
• the prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal disorder encompasses "a prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia", "a prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by a renal disorder”, and a prophylactic or therapeutic agent for both diseases of "hyperfibrinogenemia accompanied by hypercholesterolemia” and "hyperfibrinogenemia accompanied by a renal disorder”.
• Examples of the pharmaceutically acceptable carrier include those exemplified with respect to the above-mentioned "fibrinogen lowering agent comprising the compound having All antagonistic activity, a prodrug thereof, or a salt thereof".
• Examples of the dosage form of the pharmaceutical composition include oral dosage forms such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, suspensions, etc.; and parenteral forms such as injectable preparations (e.g. sustained release injectable preparations, subcutaneous injectable preparations, intravenous injectable preparations, intramuscular injectable preparations, intraperitoneal injectable preparations, intravitreous injectable preparations, etc.), drops, external preparations (e.g. compositions for nasal administration, compositions for percutaneous administration, ointments, etc.), suppositories (e.g. rectal suppositories, vaginal suppositories, etc.), pellets, drops, etc.
• injectable preparations e.g. sustained release injectable preparations, subcutaneous injectable preparations, intravenous injectable preparations, intramuscular injectable preparations, intraperitoneal injectable preparations, intravitreous injectable preparations, etc.
• the pharmaceutical composition contains the compound having renin-angiotensin inhibitory activity, a prodrug thereof, or a salt thereof in an amount of about 0.001% by weight to about 95% by weight, preferably about 0.1 by weight to about 70% by weight based on the total amount of the composition.
• the pharmaceutical composition can be prepared by conventional methods in the manufacturing technique field such as the method according to Japanese Pharmacopoeia.
• the above-mentioned preparations can be prepared by the same method as that exemplified with respect to the above "fibrinogen lowering agent comprising the compound having All antagonistic activity, a prodrug thereof, or a salt thereof".
• the dosage of the compound having renin-angiotensin inhibitory activity varies depending on a particular subject, administration route, disease, symptom, etc.
• the active component of the compound having renin-angiotensin inhibitory activity, or a prodrug thereof, or a salt thereof is orally administered to a mammal, specifically an adult (body weight 50 kg) with hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal disorder in a dose of about 0.001 to 500 mg, preferably 0.1 to 50 mg, preferably once to three times per day.
• the compound having renin-angiotensin inhibitory activity can suppress angiotensin II renal hemodynamics-induced renal disorders such as hyperlucent based on the disorder of size selecting function (i.e., permeability to such macromolecules as proteins) of glomerular basal lamina and induce an albuminuria reducing effect to serve as a good prophylactic or therapeutic agent for hyperfibrinogenemia.
• angiotensin II renal hemodynamics-induced renal disorders such as hyperlucent based on the disorder of size selecting function (i.e., permeability to such macromolecules as proteins) of glomerular basal lamina and induce an albuminuria reducing effect to serve as a good prophylactic or therapeutic agent for hyperfibrinogenemia.
• the compound having renin-angiotensin inhibitory activity which can reduce albuminuria, can also serve as a good prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia, which would otherwise be caused by an albuminuria-induced decrease in plasma proteins and acceleration of synthesis of cholesterols and plasma proteins in liver.
• the fibrinogen lowering agent or the prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal disorder of the present invention may also be used in combination with any antithrombotic or fibrinolytic agent.
• agents which can be used in combinat ion include lipid-lowering drugs, cholesterol-lowering drug s, HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibitors, insulin-sensitizing agents, therape utic agents for bone diseases, heart muscle protecting agen ts, therapeutic agents for coronary diseases, therapeutic a gents for hypertension, therapeutic agents for chronic hear t failures, therapeutic agents for diabetes, therapeutic ag ents for hypothyroidism, therapeutic agents for nephrotic s yndrome, therapeutic agents for chronic renal failures, the rapeutic agents for gynecologic diseases, and therapeutic a gents for infectious diseases.
• agents may each be ad ministered in the form of an oral preparation or a suppository such as a rectal preparation as desired.
• a component which can be used in combination include fibrates (e.g. clofibrate, bezafibrate, gemfibrozil, etc.), nicotinic acids and their derivatives and analogs (e.g. acipimox, probucol, etc.), bile acid coupling resins (e.g. colestyramine, colestipol, etc.), cholesterol absorpt ion suppressing compounds (e.g. sitosterol, neomycin, et c.), and squalene epoxidase inhibitors (e.g. NB-598 and der ivatives thereof, etc.).
• fibrates e.g. clofibrate, bezafibrate, gemfibrozil, etc.
• nicotinic acids and their derivatives and analogs e.g
• oxidesqualene-lanosterol cyclases such as decalin derivatives, azadecalin derivatives, indan derivatives, etc.
• Each of the following therapeutic agents may also be used in combination:
• Each of these agents may be used at the same time or at appropriate time interval.
• each of these agents can be used independently or mixed with each other to form a pharmaceutical composition by using a pharmaceutically acceptable carrier, vehicle, binder, diluent, or the like for oral or parenteral administration.
• a pharmaceutically acceptable carrier such as a styrene, a styrene, a styrene, a styrene, a styrene, a styrene, sulfon, or the like for oral or parenteral administration.
• separately prepared different preparations may be mixed with each other by using a diluent or the like upon administration.
• separately prepared different preparations may be administered to the same subject at the same time or at an appropriate time interval.
• the pharmaceutical composition of the present invention also include a kit product for administering separately prepared different preparations by mixing them with a diluent or the like upon administration (for example, an injectable kit comprising ampoules each containing a different powdered agent; and a diluent or the like for dissolving two or more powdered agents to form a mixture upon use); a kit product for administering separately prepared different preparations to the same subject at the same time or at an appropriate time interval (for example, a tablet kit for administrating two or more tablets at the same time or separately at an appropriate time interval which comprises two or more different tablets each containing a different agent, said tablets being contained in the same bag or different bags, if necessary, having a column for recording a given administration time(s)); and the like.
• a kit product for administering separately prepared different preparations by mixing them with a diluent or the like upon administration for example, an injectable kit comprising ampoules each containing a different powdered agent; and a diluent
• the fibrinogen lowering agent or the prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia and/or hyperfibrinogenemia accompanied by a renal disorder comprising as an effective component the compound having renin-angiotensin system inhibitory activity (e.g. the compound having All antagonistic activity or a salt thereof) of the present invention can be produced, for example, according to the following formulations.
• Components (1), (2) and (3), and 1/2 of component (4) were mixed and then granulated. To the granules was added the remainder of component (4), and the whole was filled into a gelatin capsule.
• Components (1), (2), (3), and 2/3 of component (4), and 1/2 of component (5) were mixed and then granulated. To the granules were added the remainders of components (4) and (5), followed by subjecting the mixture to compression molding.
• Candesartan cilexetil TCV-116; 0.5% methylcellulose 100 cp suspension; 1 mg/kg (2 ml/kg)
• TCV-116 0.5% methylcellulose 100 cp suspension; 1 mg/kg (2 ml/kg)
• 0.5% methylcellulose 100 cp suspensions were administered to the control group (vehicle-treated group) in a volume of 2 ml/kg.
• the blood was withdrawn from aorta abdominalis into 3.8% trisodium citrate solution (Citral, Yamanouchi Pharmaceutical Co.,Ltd., final concentration of 0.38%) and the plasma were prepared by centrifuging at 3000 rpm at room temperature for 20 minutes.
• the fibrinogen concentration was determined using fibrinogen test RD (Roche Diagnostics) and the clot timer (B-10, Sarstedt, Inc.) with reference to a standard rat fibrinogen (F-6755, Sigma).
• candesartan cilexetil (TCV-116, 1mg/kg) decreased the plasma fibrinogen level of SHC rat significantly in comparison with the control group (vehicle-treated group).
• the fibrinogen lowering agent or the prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal failure of the present invention has excellent effect of lowering fibrinogen and is useful as a prophylactic or therapeutic agent for hyperfibrinogenemia accompanied by hypercholesterolemia or hyperfibrinogenemia accompanied by a renal failure, various diseases caused by hyperfibrinogenemia, and the like.

Applications Claiming Priority (3)

Publications (2)

Family

ID=18748822

Family Applications (1)

Country Status (5)

Cited By (10)

Families Citing this family (8)

Citations (2)

Family Cites Families (5)

• 2001
  • 2001-08-24 US US10/344,719 patent/US20030187038A1/en not_active Abandoned
  • 2001-08-24 CA CA2420055A patent/CA2420055C/fr not_active Expired - Fee Related
  • 2001-08-24 EP EP01958449A patent/EP1312379A4/fr not_active Withdrawn
  • 2001-08-24 AU AU2001280135A patent/AU2001280135A1/en not_active Abandoned
  • 2001-08-24 WO PCT/JP2001/007239 patent/WO2002015935A1/fr active Application Filing

Patent Citations (2)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events